Business Context and Reporting Period
This Form 8-K Current Report was filed by Relmada Therapeutics, Inc. (Nasdaq: RLMD) on March 12, 2020, covering events occurring on March 6, 2020, and March 9, 2020. The filing primarily addresses significant changes in executive leadership within the company's research and development division.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The only financial data disclosed relates to specific executive compensation and severance arrangements:
- Severance Payment: $200,000 agreed for departing Chief Medical Officer Dr. Ottavio Vitolo.
- New Executive Salary: $475,000 annual base salary for incoming Executive Vice President Dr. Thomas Wessel.
- Sign-on Bonus: $50,000 for Dr. Wessel.
- Target Bonus: 40% of base salary for Dr. Wessel.
- Equity Grant: 350,000 stock options granted to Dr. Wessel, vesting over four years.
Material Changes
The filing reports two material personnel changes affecting the company's leadership structure:
- Departure: Dr. Ottavio Vitolo resigned as Chief Medical Officer and Head of Research and Development on March 6, 2020, to pursue other opportunities.
- Appointment: Dr. Thomas Wessel, M.D., Ph.D., was appointed Executive Vice President, Head of Research and Development, effective March 9, 2020.
Outlook, Risks, and Management Commentary
Management expressed gratitude for Dr. Vitolo's contributions. The appointment of Dr. Wessel is intended to leverage his extensive experience in drug development, specifically as a board-certified neurologist with a history of leading medical teams for three CNS products approved in the United States (Razadyne, Lunesta, and Ampyra). His background includes previous roles as Chief Medical Officer at Acorda Therapeutics, Flex Pharma, and Asceneuron.
Compensation Terms and Risks:
- Dr. Wessel's employment is "at-will," allowing termination by either party at any time.
- Severance for Dr. Wessel includes six months of compensation and health benefits if terminated without cause.
- The agreement includes a 24-month non-solicitation clause post-employment.
Investor Verification Checklist
- Verify the impact of the leadership transition on the company's ongoing clinical trial timelines and drug development pipeline.
- Review the full text of the Wessel Employment Agreement (Exhibit 10.1) for detailed vesting schedules and performance metrics.
- Assess the company's cash position to ensure it can sustain the new executive compensation package and severance obligations.
- Monitor future filings for any additional changes to the executive team or strategic direction following this transition.